Abstract
Introduction: Regimens involving intensive immuno-chemotherapy, followed by high-dose therapy and autologous stem cell transplant represent the standard treatment for younger fit patients with mantle cell lymphoma (MCL). Targeted approaches (i.e. ibrutinib, bortezomib, and lenalidomide) represent the backbone of therapy for relapsed cases. Areas covered: Acalabrutinib is a novel small molecule with a butynamide moiety specifically designed to irreversibly inhibit Bruton tyrosine kinase (BTK), which is more potent and selective than ibrutinib. Relevant publications have been identified through literature searches using the terms ‘mantle cell lymphoma’ and ‘acalabrutinib’. Expert opinion: Acalabrutinib has been approved for the treatment of relapsed/refractory (RR) MCL patients. To date, clinical trials have reported some adverse effects such as cardiac toxicity or atrial fibrillation. Acalabrutinib in combination with other drugs, either in chemo-containing or chemo-free schedules, represent a valid option for MCL. However, none of the treatment schedules containing BTK inhibitors have been shown to be curative in MCL. Acalabrutinib may ultimately represent an option for patients who are ‘fit’ and exhibit well-controlled disease, which often characterizes only a limited ‘niche’ among MCL patients.
| Original language | English |
|---|---|
| Journal | Expert Opinion on Pharmacotherapy |
| DOIs | |
| Publication status | Accepted/In press - Jan 1 2019 |
Fingerprint
Keywords
- Acalabrutinib
- BTK
- MCL
- therapy
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. / Morabito, Fortunato; Recchia, Anna Grazia; Vigna, Ernesto; Botta, Cirino; Skafi, Mamdouh; Abu-Rayyan, Mohammed; Atrash, Moien; Galimberti, Sara; Morabito, Lucio; Al-Janazreh, Hamdi; Martino, Massimo; Cutrona, Giovanna; Gentile, Massimo.
In: Expert Opinion on Pharmacotherapy, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma
AU - Morabito, Fortunato
AU - Recchia, Anna Grazia
AU - Vigna, Ernesto
AU - Botta, Cirino
AU - Skafi, Mamdouh
AU - Abu-Rayyan, Mohammed
AU - Atrash, Moien
AU - Galimberti, Sara
AU - Morabito, Lucio
AU - Al-Janazreh, Hamdi
AU - Martino, Massimo
AU - Cutrona, Giovanna
AU - Gentile, Massimo
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Introduction: Regimens involving intensive immuno-chemotherapy, followed by high-dose therapy and autologous stem cell transplant represent the standard treatment for younger fit patients with mantle cell lymphoma (MCL). Targeted approaches (i.e. ibrutinib, bortezomib, and lenalidomide) represent the backbone of therapy for relapsed cases. Areas covered: Acalabrutinib is a novel small molecule with a butynamide moiety specifically designed to irreversibly inhibit Bruton tyrosine kinase (BTK), which is more potent and selective than ibrutinib. Relevant publications have been identified through literature searches using the terms ‘mantle cell lymphoma’ and ‘acalabrutinib’. Expert opinion: Acalabrutinib has been approved for the treatment of relapsed/refractory (RR) MCL patients. To date, clinical trials have reported some adverse effects such as cardiac toxicity or atrial fibrillation. Acalabrutinib in combination with other drugs, either in chemo-containing or chemo-free schedules, represent a valid option for MCL. However, none of the treatment schedules containing BTK inhibitors have been shown to be curative in MCL. Acalabrutinib may ultimately represent an option for patients who are ‘fit’ and exhibit well-controlled disease, which often characterizes only a limited ‘niche’ among MCL patients.
AB - Introduction: Regimens involving intensive immuno-chemotherapy, followed by high-dose therapy and autologous stem cell transplant represent the standard treatment for younger fit patients with mantle cell lymphoma (MCL). Targeted approaches (i.e. ibrutinib, bortezomib, and lenalidomide) represent the backbone of therapy for relapsed cases. Areas covered: Acalabrutinib is a novel small molecule with a butynamide moiety specifically designed to irreversibly inhibit Bruton tyrosine kinase (BTK), which is more potent and selective than ibrutinib. Relevant publications have been identified through literature searches using the terms ‘mantle cell lymphoma’ and ‘acalabrutinib’. Expert opinion: Acalabrutinib has been approved for the treatment of relapsed/refractory (RR) MCL patients. To date, clinical trials have reported some adverse effects such as cardiac toxicity or atrial fibrillation. Acalabrutinib in combination with other drugs, either in chemo-containing or chemo-free schedules, represent a valid option for MCL. However, none of the treatment schedules containing BTK inhibitors have been shown to be curative in MCL. Acalabrutinib may ultimately represent an option for patients who are ‘fit’ and exhibit well-controlled disease, which often characterizes only a limited ‘niche’ among MCL patients.
KW - Acalabrutinib
KW - BTK
KW - MCL
KW - therapy
UR - http://www.scopus.com/inward/record.url?scp=85075116099&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075116099&partnerID=8YFLogxK
U2 - 10.1080/14656566.2019.1689959
DO - 10.1080/14656566.2019.1689959
M3 - Article
AN - SCOPUS:85075116099
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
ER -